International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7874455
Original Article
Study of Trial of Labour after Caesarean Section (TOLAC)
 ,
 ,
 ,
Published
April 28, 2023
Abstract
Introduction: Caesarean section is one of the most commonly performed major surgical procedures. Worldwide increase in caesarean section (CS) rate during the last three decades has been the cause for concern. As ours is a tertiary health care centre catering around 20,000 deliveries per year and patients with previous caesarean scar get referred from surrounding primary health centers in huge number. In order to reduce c-section rates, TOLAC are conducted as per departmental standard operative procedures and WHO standards. Objective: To study incidence of trial of labour after c-section, progress of labour in active phase, maternal and fetal outcome in cases of trial of labour after c-section at tertiary care center. Methods: Prospective Observational study in tertiary institute from october 2020- september 2022 in the department of obgy. Ethical approval was taken. 200 cases were studied after applying inclusion and exclusion criteria with CTG monitoring. Results: A total of 200 subjects with previous one cesarean section were studied. 71.50% underwent successful trial of vaginal birth (57.50 % vbac, 08.50 % vaccum and 05.50 % forceps) and 28.50% required cesarean section. Maximum number of women who had VBAC has LSCS (Lower Segment Caesarean Section) in the past for fetal distress(33%). LSCS (failed VBAC) was done maximally for fetal distress 37 (64.90%), then for failure to progress 15 (26.30%) and impending scar dehiscence 5 (08.80%). Maternal complications were lower in the VBAC group: fever (0.69%), blood transfusion (06.30 %). Conclusion: Success rate of TOLAC at our institute is 75 %.The study shows encouraging result for VBAC in a well facilitated set up to be followed to reduce Caesarean rate.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
1376 Views
31 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved